GMAB
Genmab AS
NASDAQ: GMAB · HEALTHCARE · BIOTECHNOLOGY
$26.11
-2.54% today
Updated 2026-04-29
Market cap
$16.45B
P/E ratio
17.40
P/S ratio
4.42x
EPS (TTM)
$1.54
Dividend yield
—
52W range
$19 – $35
Volume
1.7M
WallStSmart proprietary scores
54
out of 100
Grade: C
Hold
Investment rating
2.7
Growth
F8.5
Quality
A8.5
Profitability
A7.3
Valuation
B+2/9
Piotroski F-Score
Weak
3.9
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$37.68
+44.31%
12-Month target
$25.57
-2.07%
Intrinsic (DCF)
$58.29
Margin of safety
+48.43%
0 Strong Buy8 Buy3 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.90 — safe zone
+ Profit margin 25.90% — above average
+ Free cash flow $287.35M — positive
+ 48.43% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $14.51B | $16.47B | $21.53B | $3.72B | $3.72B |
| Net income | $5.45B | $4.35B | $7.84B | $963.76M | $30.91M |
| EPS | — | — | — | — | $1.54 |
| Free cash flow | $3.60B | $7.00B | $7.58B | $1.15B | $287.35M |
| Profit margin | 37.59% | 26.42% | 36.44% | 25.89% | 25.90% |
Peer comparison
Smart narrative
Genmab AS trades at $26.11. representing a P/E of 17.40x trailing earnings. Our Smart Value Score of 54/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 3.90, it sits in the safe zone. TTM revenue stands at $3.72B. with profit margins at 25.90%. Our DCF model estimates intrinsic value at $58.29.
Frequently asked questions
What is Genmab AS's stock price?
Genmab AS (GMAB) trades at $26.11.
Is Genmab AS overvalued?
Smart Value Score 54/100 (Grade C, Hold). DCF value $58.29.
What is the price target of Genmab AS (GMAB)?
The analyst target price is $37.68, representing +44.3% upside from the current price of $26.11.
What is the intrinsic value of Genmab AS (GMAB)?
Based on our DCF model, intrinsic value is $58.29, a +48.4% margin of safety versus $26.11.
What is Genmab AS's revenue?
TTM revenue is $3.72B.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
3.90 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.42x
ROE17.50%
Beta0.74
50D MA$27.59
200D MA$28.71
Shares out0.61B
Float0.06B
Short ratio—
Avg volume1.7M
Performance
1 week-3.22%
1 month-2.68%
3 months-21.71%
YTD-15.23%
1 year—
3 years—
5 years—